ABVX: the "$3B" figure is a market-share illustration, not peak sales guidance
The sell-off on 15 September (ABVX -5.7% to ~$107, versus a prior close of $113.58) traces back to a misreading of management's comments at the Morgan Stanley Global Healthcare Conference fireside. The X thread captures the essence correctly, and the MS note (Judah Frommer, 15 September, Overweight, price target $180, market cap $10.8B) provides the precise wording, so it is worth setting out exactly what was said.
What management said. Citing Evaluate Pharma data already on slide 5 of the corporate presentation, the US UC market is expected to grow from ~$6B today to ~$15B in 2032. As a directional illustration, management noted that ~20% share of that 2032 US market would equate to ~$3B of US sales in 2032. That is the full extent of the comment: a share-of-market arithmetic exercise on a single year, in a single geography, in a single indication.
What management did not say. There was no peak sales guidance. MS caught up with management after the session, and the note states explicitly that the comments "are not tied to peak sales" and that the peak sales opportunity for obefazimod is "materially greater" once pricing, durability, ex-US markets, Crohn's disease and market growth beyond 2032 are taken into account. The reply in the thread ("if they said $3B in 2032, isn't that bearish?") is therefore built on a false premise: $3B is a partial-scope illustration, not a ceiling for the franchise.
Why the number is not bearish even taken at face value. A single-indication, single-market, single-year figure of ~$3B, reached only a few years after launch, is a ramp point, not a plateau. Excluded from it: EU and Japan UC, Crohn's (Ph2b topline on track for mid-2027), price evolution, persistence beyond the 2032 snapshot, and the further expansion of the oral advanced-therapy market that management's own research anticipates. For reference, the MS $180 price target rests on a DCF with explicit revenue projections through 2035, an 11.5% discount rate and 0% terminal growth, and MS models the company turning profitable in 2028 (EPS $1.89e). None of that framework was changed by the fireside.
What actually mattered in the fireside. The substantive takeaways were all supportive: GI advisory boards are not concerned by the ABTECT malignancy cases given patient risk factors and elevated background malignancy rates in IBD; management does not expect a black box warning and considers it very possible that the label carries no malignancy warning at all; both 25mg and 50mg doses are being pursued for the label with flexible language; multiple new presentations are coming at UEG (17 to 20 October), including maintenance data by prior advanced-therapy exposure and line of therapy, plus long-term Ph2 persistence data; the pre-NDA meeting has been held and filing remains on track for YE26.
Bottom line. The stock sold off on a second-hand misquote that both the company and the hosting broker have now corrected. Nothing in the fireside changed the fundamental case; if anything, the labeling commentary and the UEG data flow are incrementally positive. Against a 52-week range of $69.81 to $148.83 and an unchanged $180 target, we would treat the weakness as noise ahead of UEG and the NDA filing rather than as new information.